The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer

Histopathology

Volumn 61, Issue 2, 2012, Pages 153-161

  Fanelli, Marcello Ferretti ^a   Chinen, Ludmilla T Domingos ^a   Begnami, Maria Dirlei ^a   Costa, Wilson Luis ^a   Fregnami, José Humberto T ^a   Soares, Fernando A ^a   Montagnini, André Luis ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Epithelial mesenchymal transition; Gastric cancer; Molecules

Indexed keywords

CD44V6 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; GELATINASE B; MATRILYSIN; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HEMATOGENEOUS INVASION; HUMAN; HUMAN TISSUE; LYMPHATIC INVASION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PERINEURAL INVASION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STOMACH BIOPSY; STOMACH CANCER; TUMOR GROWTH;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; CYCLOOXYGENASE 2; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTORS, CXCR4; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84864388728     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04139.x     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61; 69-90.
2. Wu CW, Hsiung CA, Lo SS et al. Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol. 2006; 7; 309-315.
3. Hsu KW, Hsieh RH, Wu CW et al. MBP-1 suppresses growth and metastasis of gastric cancer cells through COX-2. Mol. Biol. Cell 2009; 20; 5127-5137.
4. Fanelli MF, de Paiva TF Jr, Silva MJ et al. Predictors of peritoneal carcinomatosis in patients with gastric cancer treated at a single institution in Brazil. J. Surg. Oncol. 2009; 100; 452-455.
5. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002; 2; 442-454.
6. Shook D, Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech. Dev. 2003; 120; 1351-1383.
7. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005; 8; 86-94.
8. Celikel C, Eren F, Gulluoglu B, Bekiroglu N, Turhal S. Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas: prognostic implications. Pathol. Oncol. Res. 2007; 13; 215-226.
9. Sun WH, Sun YL, Fang RN et al. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn. J. Clin. Oncol. 2005; 35; 707-713.
10. Lazar D, Taban S, Ardeleanu C et al. Immunohistochemical expression of the cyclooxygenase-2 in gastric cancer. The correlations with the tumor angiogenesis and patients' survival. Rom. J. Morphol. Embryol. 2008; 49; 371-379.
11. Zhang M, Zhu GY, Gao HY, Zhao SP, Xue Y. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric adenocarcinoma. J. Surg. Oncol. 2011; 103; 243-247.
12. Nelson AR, Fingleton B, Rothenberg ML, Mastrisian ML. Matrix metalloproteinases: biologial activity and clinical implications. J. Clin. Oncol. 2000; 18; 1135-1149.
13. Yoshie O. Role of chemocines in trafficking of lymphocytes and dendritic cells. Int. J. Hematol. 2000; 72; 399-407.
14. Silva E, Begnami MD, Fregnami JHTG et al. Cadherin-catenin adhesion system and mucin expression: a comparison between young and older patients with gastric carcinoma. Gastric Cancer 2008; 11; 149-159.
15. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999; 17; 1474-1481.
16. Kim MA, Lee HS, Lee HE, Kim JH, Yang HK, Kim WH. Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma. Histopathology 2009; 54; 442-451.
17. Gotzmann J, Mikula M, Eger A et al. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat. Res. 2004; 566; 9-20.
18. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 2006; 172; 973-981.
19. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007; 39; 305-318.
20. Peach RJ, Hollenbaugh D, Stamenkovic I, Aruffo A. Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J. Cell Biol. 1993; 122; 257-264.
21. Yamamichi K, Uehara Y, Kitamura N, Nakane Y, Hioki K. Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and prognosis in gastric cancer. Int. J. Cancer 1998; 79; 256-262.
22. Xin Y, Grace A, Gallagher MM, Curran BT, Leader MB, Kay EW. CD44V6 in gastric carcinoma: a marker of tumor progression. Appl. Immunohistochem. Mol. Morphol. 2001; 9; 138-142.
23. Tahara E. Molecular mechanism of stomach carcinogenesis. J. Cancer Res. Clin. Oncol. 1993; 119; 265-272.
24. Yasui W, Oue N, Kuniyasu H, Ito R, Tahara E, Yokozaki H. Molecular diagnosis of gastric cancer: present and future. Gastric Cancer 2001; 4; 113-121.
25. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 2003; 112; 1776-1784.
26. Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J. Mammary Gland Biol. Neoplasia 2009; 14; 29-43.
27. Werner M, Becker KF, Keller G, Hofler H. Gastric adenocarcinoma: pathomorphology and molecular pathology. J. Cancer Res. Clin. Oncol. 2001; 127; 207-216.
28. Murata H, Kawano S, Tsuji S et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am. J. Gastroenterol. 1999; 94; 451-455.
29. Yamamoto H, Itoh F, Fukushima H, Hinoda Y, Imai K. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability. Int. J. Cancer 1999; 84; 400-403.
30. Lim YH, Joo JH, Choi HJ et al. Increased expression of cyclooxygenase-2 protein in human gastric cancer. Clin. Cancer Res. 2000; 6; 519-525.
31. Chen NC, Sung TC, Lin TM, Lee HP, Chang JK. Clinicopathologic association of cyclooxygenase-1 and cyclooxygenase-2 expression in gastric adenocarcinomas. Ann. Surg. 2001; 233; 183-188.
32. Mrena J, Wiksten JP, Thiel A et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin. Cancer Res. 2005; 11; 7362-7368.
33. Kabashima A, Maehara Y, Kakeji Y, Baba H, Koga T, Sugimachi K. Clinicopathological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin. Cancer Res. 2000; 6; 3581-3584.
34. 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenviroment. Carcinogenesis 2009; 30; 377-386.
35. Yamashita K, Mori M, Shiraishi T, Shibuta K, Sugimachi K. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin. Cancer Res. 2000; 6; 1169-1174.
36. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J. Natl Cancer Inst. 1999; 91; 1113-1124.
37. Braun S, Pantel K, Muller P et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 2000; 342; 525-533.
38. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410; 50-56.
39. Yasumoto K, Koizumi K, Kawashima A et al. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res. 2006; 66; 2181-2187.
40. Murakami T, Cardones AR, Hwang ST. Chemokine receptors and melanoma metastasis. J. Dermatol. Sci. 2004; 36; 71-78.
41. Hashimoto I, Koizumi K, Tatematsu M et al. Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur. J. Cancer 2008; 44; 1022-1029.
42. Billadeau DD, Chatterjee S, Bramati P et al. Characterization of the CXCR4 signaling in pancreatic cancer cells. Int. J. Gastrointest. Cancer 2006; 37; 110-119.